<DOC>
	<DOCNO>NCT01589978</DOCNO>
	<brief_summary>This study design observe clinical outcome patient receive PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System routine clinical practice . Patients symptomatic heart disease document silent ischemia . This prospective , open-label consecutively-enrolling study . Clinical follow-up 5 year . Approximately 2,689 patient enrol 65 center United States .</brief_summary>
	<brief_title>PROMUS Element Plus US Post-Approval Study</brief_title>
	<detailed_description>The wide-spread use drug-eluting stent ( DES ) evolve standard care de novo lesion . The PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System indicate improve luminal diameter patient symptomatic heart disease document silent ischemia due de novo lesion native coronary artery ≥2.25 mm ≤4.00 mm diameter lesion ≤34 mm length . The propose study compile real-world clinical outcome data PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System routine clinical practice . Patients enrol study expect follow antiplatelet therapy recommendation per American College Cardiology ( ACC ) /American Heart Association ( AHA ) /Society Cardiovascular Angiography Interventions ( SCAI ) guideline percutaneous coronary intervention ( PCI ) . Recommended medication include aspirin , take 3 day prior procedure peri-procedural loading dose continue indefinitely . Additionally , one follow P2Y12 antagonist may give peri-procedural load dose maintenance dose per physician discretion : clopidogrel , prasugrel , ticagrelor , ticlopidine .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Salicylic Acid</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>The population include consecutive , consented patient . There exclusion criterion allcomers study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>drug-eluting stent</keyword>
	<keyword>DES</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>everolimus</keyword>
</DOC>